Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas

被引:84
|
作者
Rossi, Marco [1 ,2 ]
Gay, Lorenzo [1 ,2 ]
Ambrogi, Federico [3 ]
Nibali, Marco Conti [1 ,2 ]
Sciortino, Tommaso [1 ,2 ]
Puglisi, Guglielmo [1 ,2 ]
Leonetti, Antonella [1 ,2 ]
Mocellini, Cristina [4 ]
Caroli, Manuela [5 ]
Cordera, Susanna [6 ]
Simonelli, Matteo [7 ]
Pessina, Federico [7 ]
Navarria, Piera [7 ]
Pace, Andrea [8 ]
Soffietti, Riccardo [9 ]
Ruda, Roberta [9 ]
Riva, Marco [1 ,2 ]
Bello, Lorenzo [1 ,2 ]
机构
[1] Univ Milan, Dept Oncol & Hematooncol, Neurosurg Oncol Unit, Milan, Italy
[2] IRCCS Ist Ortoped Galeazzi, Neurosurg Oncol Unit, Milan, Italy
[3] Univ Milan, Dept Clin Sci & Community Hlth, Lab Med Stat Biometry & Epidemiol GA Maccararo, Milan, Italy
[4] Osped Santa Croce & Carle, Neurooncol, Div Neurol, Cuneo, Italy
[5] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Neurochirurg, Milan, Italy
[6] Osped Reg Parini, Div Neurol, Neurooncol, Aosta, Italy
[7] IRCCS, Humanitas Canc Ctr, Humanitas Res Hosp, Rozzano, Italy
[8] Ist Nazl Tumori Regina Elena, Neurooncol, Rome, Italy
[9] Univ Torino, Citta Salute & Sci, Neurooncol, Turin, Italy
关键词
lower-grade gliomas; malignant progression-free survival; overall survival; progression-free survival; supratotal resection; RESPONSE ASSESSMENT; SURGICAL RESECTION; II GLIOMAS; DIFFUSE; SURGERY; NEUROONCOLOGY; MANAGEMENT; SAFETY;
D O I
10.1093/neuonc/noaa225
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Supratotal resection is advocated in lower-grade gliomas (LGGs) based on theoretical advantages but with limited verification of functional risk and data on oncological outcomes. We assessed the association of supratotal resection in molecularly defined LGGs with oncological outcomes. Methods. Included were 460 presumptive LGGs; 404 resected; 347 were LGGs, 319 isocitrate dehydrogenase (IDH)-mutated, 28 wildtype. All patients had clinical, imaging, and molecular data. Resection aimed at supratotal resection without any patient or tumor a priori selection. The association of extent of resection (EOR), categorized on volumetric fluid attenuated inversion recovery images as residual tumor volume, along with postsurgical management with progression-free survival (PFS), malignant (M)PFS, and overall survival (OS) assessed by univariate, multivariate, and propensity score analysis. The study mainly focused on IDH-mutated LGGs, the "typical LGGs." Results. Median follow-up was 6.8 years (interquartile range, 5-8). Out of 319 IDH-mutated LGGs, 190 (59.6%) progressed, median PFS: 4.7 years (95% CI: 4-5.3). Total and supratotal resection obtained in 39% and 35% of patients with IDH1-mutated tumors. In IDH-mutated tumors, most patients in the partial/subtotal group progressed, 82.4% in total, only 6 (5.4%) in supratotal. Median PFS was 29 months (95% CI: 25-36) in subtotal, 46 months (95% CI: 38-48) in total, while at 92 months, PFS in supratotal was 94.0%. There was no association with molecular subtypes and grade. At random forest analysis, PFS strongly associated with EOR, radiotherapy, and previous treatment. In the propensity score analysis, EOR associated with PFS (hazard ratio, 0.03; 95% CI: 0.01-0.13). MPFS occurred in 32.1% of subtotal total groups; 1 event in supratotal. EOR, grade III, previous treatment correlated to MPFS. At random forest analysis, OS associated with EOR as well. Conclusions. Supratotal resection strongly associated with PFS, MPFS, and OS in LGGs, regardless of molecular subtypes and grade, right from the beginning of clinical presentation.
引用
收藏
页码:812 / 826
页数:15
相关论文
共 50 条
  • [41] ANALYSIS OF THE CORRELATION OF TIME TO TREATMENT FAILURE WITH OVERALL SURVIVAL VERSUS CORRELATION OF PROGRESSION-FREE SURVIVAL WITH OVERALL SURVIVAL
    Gibson, G. D.
    Henegan, J. C.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2022, 70 (02) : 548 - 548
  • [42] Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John Frederick
    Goss, Glenwood D.
    Fung-Kee-Fung, Michael
    Jonker, Derek J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Prognostic Factors for Progression-free Survival and Overall Survival Αfter Recurrence of Glioblastoma
    Zemskova, Oksana
    Yu, Nathan y.
    Leppert, Jan
    Rades, Dirk
    ANTICANCER RESEARCH, 2024, 44 (07) : 3059 - 3066
  • [44] Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma
    Wani, Kashmira
    Gutta, Radhika
    Mittal, Aayush
    Jamil, Maria
    Springer, Kylie
    Kuriakose, Philip
    BLOOD, 2023, 142
  • [46] RELATIONSHIP BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Beauchemin, C.
    Johnston, J.
    Lapierre, M. E.
    Aissa, F.
    Lachaine, J.
    VALUE IN HEALTH, 2012, 15 (07) : A414 - A415
  • [47] Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study
    Zhang, Lijun
    Ko, Chia-Wen
    Tang, Shenghui
    Sridhara, Rajeshwari
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2013, 47 (01) : 95 - 100
  • [48] Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
    Beauchemin, Catherine
    Cooper, Dan
    Lapierre, Marie-Eve
    Yelle, Louise
    Lachaine, Jean
    ONCOTARGETS AND THERAPY, 2014, 7 : 1101 - 1110
  • [49] Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study
    Lijun Zhang
    Chia-Wen Ko
    Shenghui Tang
    Rajeshwari Sridhara
    Therapeutic Innovation & Regulatory Science, 2013, 47 : 95 - 100
  • [50] RELATIONSHIP BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Beauchemin, C.
    Johnston, J. B.
    Lapierre, M.
    Aissa, F.
    Lachaine, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 350 - 350